It has been reported to be a cell-active ubiquitination inhibitor in prostate cancer that selectively degrades Skp2 and upregulates FBXW2 expression, thus inducing autophagy and inhibiting cancer cell growth. This evidence concerns the gene SKP2 and prostate cancer.